Suven Life Sciences is currently trading at Rs 225.90, up by 4.05 points or 1.83% from its previous closing of Rs 221.85 on the BSE.
The scrip opened at Rs 224.95 and has touched a high and low of Rs 227.85 and Rs 222.65 respectively. So far 16998 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs 337.70 on 11-Sep-2018 and a 52 week low of Rs 163.30 on 23-Mar-2018.
Last one week high and low of the scrip stood at Rs 231.70 and Rs 216.90 respectively. The current market cap of the company is Rs 2850.49 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 7.91% and 32.09% respectively.
Suven Life Sciences (Suven) has secured one product patent from Brazil and one product patent from Eurasia corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2023 and 2034 respectively.
The granted claims of the patents include the class of selective 5-HT6 and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia etc.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |